And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the lifestyle of those living with it. Here are five ways that this skin condition ...

Bimzelx, approved for psoriasis and hidradenitis suppurativa, is forecasted to become a blockbuster, potentially generating over €6 billion in peak sales. UCB maintains solid EBITDA margins and ...

The approved indications for bimekizumab in the EU are: Plaque psoriasis: Bimekizumab is indicated for the ... each containing 320 mg of Bimzelx (bimekizumab-bkzx). These new device presentations add ...

Bimekizumab (Bimzelx; UCB) is a dual IL-17A and IL-17F inhibitor with current indications to treat moderate to severe plaque psoriasis, active psoriatic arthritis, active nonradiographic axial ...

Patients with moderate to severe HS experienced sustained symptomatic and quality-of-life improvements with the monoclonal ...

Otezla set the stage for oral psoriasis treatments, but a massive unmet need for ... sonelokimab that meets the bar set by its IL-17 competitors such as Cosentyx and Bimzelx, as well as original ...

Shares of biotech firm UCB (OTCPK:UCBJF) spiked after the FDA approved Bimzelx® for psoriatic arthritis, a painful joint condition affecting 30% of psoriasis patients. Bimzelx® has become the ...

Dice’s lead product candidate is oral IL-17 inhibitor DC-806, which is in phase 2 testing as a treatment for plaque psoriasis ... (brodalumab), and UCB’s Bimzelx (bimekizumab).

1) Bimekizumab: UCB's first-in-class dual IL-17 A/F inhibitor was approved in the EU last year as Bimzelx but turned ... for moderate to severe plaque psoriasis therapies thanks to superior ...